Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
Abstract Small molecules targeting the EGFR tyrosine kinase domain have been used with some success at treating patients with non-small cell lung cancer driven by activating mutations in the kinase domain. The initial class of inhibitors displaced ATP noncovalently but were rendered ineffective due...
Guardado en:
Autores principales: | Srinivasaraghavan Kannan, Mohan R. Pradhan, Garima Tiwari, Wei-Chong Tan, Balram Chowbay, Eng Huat Tan, Daniel Shao-Weng Tan, Chandra Verma |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/145a6170f8624c79b228e5d534e4ff3b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
por: Huanhuan Xu, et al.
Publicado: (2021) -
Angiopoietin-like 4 regulates epidermal differentiation.
por: Mintu Pal, et al.
Publicado: (2011) -
Afatinib treatment in advanced non-small cell lung cancer
por: Hurwitz JL, et al.
Publicado: (2011) -
Role of afatinib in the treatment of advanced lung squamous cell carcinoma
por: Vavalà T
Publicado: (2017) -
Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report
por: Lander Van Acker, et al.
Publicado: (2021)